NYRADA INC (ASX:NYR) 8 Looking Forward and Conclusion We remain well-placed to achieve our goals. Nyrada's operating environment continues to be one of the best places in the world for cost-effective drug development. Australia boasts a strong and stable legal environment, produces gifted and talented scientists from a world-class university system, and benefits from a supportive governmental research and development rebate scheme. We are also excited to be collaborating with the largest potential customer in the world, the US military, in developing our drug therapy. Collectively, we strive to continue to deliver significant progress. I take this opportunity to thank my fellow Non-Executive Directors for their diligence and focus, our CEO James Bonnar for his leadership of the Company, and the Nyrada team for their efforts and insights. To my fellow stockholders, I thank you again for your ongoing support and your confidence in our efforts to reach our goals. As we move forward, we remain dedicated to delivering on our commitments. We eagerly anticipate sharing more updates and successes with you in the coming months. Together, we can turn opportunities into reality, discovery into therapies, and innovation into shareholder value. Warm regards, John Moore Non-Executive Chair “There are no current FDA-approved therapies for TBI, which is experienced by over 70 million people worldwide each year. The estimated annual healthcare cost of non-fatal TBIs is over US$40 billion in the US alone.”
RkJQdWJsaXNoZXIy MjE2NDg3